Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients

Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors. The reduction in glucose reabsorption in proximal tubuli induced by SGLT2 inhibitors increases urinary glucose and sodium excretion resulting...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubica, Jacek, Kubica, Aldona, Grzelakowska, Klaudyna, Stolarek, Wioleta, Grąbczewska, Zofia, Michalski, Piotr, Niezgoda, Piotr, Bartuś, Stanisław, Budaj, Andrzej, Dąbrowski, Mariusz, Drożdż, Jarosław, Gellert, Ryszard, Jaguszewski, Miłosz J., Jankowski, Piotr, Legutko, Jacek, Lesiak, Maciej, Leszek, Przemysław, Małyszko, Jolanta, Mitkowski, Przemysław, Nessler, Jadwiga, Pawlaczyk, Krzysztof, Siller-Matula, Jolanta, Stompór, Tomasz, Wolnik, Bogumił, Navarese, Eliano Pio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2023
Materias:
Clinical Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987542/
https://www.ncbi.nlm.nih.gov/pubmed/34708866
http://dx.doi.org/10.5603/CJ.a2021.0133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987542/
https://www.ncbi.nlm.nih.gov/pubmed/34708866
http://dx.doi.org/10.5603/CJ.a2021.0133

Ejemplares similares